#Taiwan #Taipei #HCC #TCM Biotech #CatCHimera

TCM Biotech Achieves FDA Breakthrough for CatCHimera

TCM Biotech (TPEx: 4169) has recently made waves in the medical diagnostics field by obtaining FDA Breakthrough Device Designation for its innovative liquid biopsy platform, CatCHimera. This significant development aims to enhance the monitoring of minimal residual disease (MRD) in patients recovering from hepatocellular carcinoma (HCC), a pressing medical concern given the high rates of recurrence associated with liver cancer.

Understanding CatCHimera

CatCHimera operates on a groundbreaking premise: instead of using conventional somatic mutations, it leverages HBV–host genome integration junctions as unique circulating biomarkers for tracking tumor presence. This approach sets it apart from current ctDNA MRD assays, which rely on somatic single nucleotide variants (SNVs) or indels. The utilization of HBV integration sites allows for a more personalized and precise assessment of the disease, making it an invaluable tool for post-treatment monitoring.

Clinical Performance Data

Recent studies have shown promising results for CatCHimera’s capabilities. Published clinical data indicate that

• - vh-DNA was detected in 98% of pre-surgical plasma samples.
• - The platform boasts a detection limit of approximately 1.5 cm, providing physicians with a sensitive monitoring tool.
• - The average lead time for detecting recurrence surpasses conventional methods, with a 158-day advantage over CT imaging.
• - Notably, the negative predictive value (NPV) stands at 92%, while the positive predictive value (PPV) is 71% for post-operative recurrence detection.
• - When combined with other biomarkers like AFP and PIVKA-II, it achieves a stellar 95.8% sensitivity and 95.5% specificity, once again confirming its robustness in identifying tumors smaller than 5 cm.

The Urgency of Addressing HCC

HCC is a critical issue in the realm of cancer treatment, being the third leading cause of cancer deaths globally. Despite the severe statistics, there hasn’t been a significant focus on ctDNA MRD platforms for liver cancer until CatCHimera's emergence. The platform specifically caters to the substantial population of roughly 296 million chronic HBV carriers worldwide, who are at heightened risk of developing HCC. This further emphasizes the necessity of advanced diagnostic tools in monitoring this devastating disease.

Collaborative Development

The development of CatCHimera was in conjunction with a prominent group led by Academician Pei-Jer Chen at National Taiwan University, showcasing a fruitful collaboration between academia and industry. Moreover, this project holds international patent protections across multiple countries, including the US, EU, Singapore, and China, reflecting its potential global impact.

TCM Biotech's molecular diagnostics laboratory operates under the Taiwan Food and Drug Administration (TFDA) laboratory-developed test accreditation, which adds to the credibility of this transformative technology.

Conclusion

As TCM Biotech continues its mission to enhance cancer diagnostics and patient outcomes, CatCHimera stands as a beacon of hope, promising to revolutionize the monitoring process for HCC and ultimately alter the trajectory of treatment and recovery for countless patients worldwide. With FDA Breakthrough Designation in hand, the future looks bright for both this innovative platform and the patients it aims to serve.